Zegerid Switch Application Expected Before May – Santarus
This article was originally published in The Tan Sheet
Executive Summary
Schering-Plough is expected to file a switch application for Santarus' proton pump inhibitor Zegerid with FDA before May, according to the San Diego-based specialty pharmaceutical firm